OA11946A - Ziprasidone suspension. - Google Patents

Ziprasidone suspension. Download PDF

Info

Publication number: OA11946A
Authority: OA; OAPI
Prior art keywords: composition; ziprasidone; chloride; polysorbate; sait
Prior art date: 1999-05-27

Application number

OA1200100304A

Other languages

English (en)

Inventor

Daniel Ray Arenson

Hong Qi

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-27

Filing date

2000-05-08

Publication date

2006-04-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22472103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11946(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-05-08 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2006-04-13 Publication of OA11946A publication Critical patent/OA11946A/en

Links

229960000607 ziprasidone Drugs 0.000 title claims abstract description 43
MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title claims abstract description 43
239000000725 suspension Substances 0.000 title description 31
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 36
239000000203 mixture Substances 0.000 claims abstract description 30
229920000136 polysorbate Polymers 0.000 claims abstract description 24
229950008882 polysorbate Drugs 0.000 claims abstract description 21
239000002253 acid Substances 0.000 claims abstract description 17
239000012458 free base Substances 0.000 claims abstract description 14
239000003795 chemical substances by application Substances 0.000 claims description 27
239000000377 silicon dioxide Substances 0.000 claims description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
ZCBZSCBNOOIHFP-UHFFFAOYSA-N ziprasidone hydrochloride hydrate Chemical group [H+].O.[Cl-].C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 ZCBZSCBNOOIHFP-UHFFFAOYSA-N 0.000 claims description 17
235000012239 silicon dioxide Nutrition 0.000 claims description 16
229960003474 ziprasidone hydrochloride Drugs 0.000 claims description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 9
239000003513 alkali Substances 0.000 claims description 7
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 6
239000006068 taste-masking agent Substances 0.000 claims description 6
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
239000001103 potassium chloride Substances 0.000 claims description 3
235000011164 potassium chloride Nutrition 0.000 claims description 3
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
239000001110 calcium chloride Substances 0.000 claims description 2
229910001628 calcium chloride Inorganic materials 0.000 claims description 2
150000001805 chlorine compounds Chemical class 0.000 claims 4
241001043916 Saitis Species 0.000 claims 1
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
150000003839 salts Chemical class 0.000 abstract description 8
239000007900 aqueous suspension Substances 0.000 abstract description 4
229960001866 silicon dioxide Drugs 0.000 description 14
239000002245 particle Substances 0.000 description 11
238000009472 formulation Methods 0.000 description 10
238000002156 mixing Methods 0.000 description 8
238000009736 wetting Methods 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
239000003921 oil Substances 0.000 description 7
235000019198 oils Nutrition 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
229940079593 drug Drugs 0.000 description 6
239000003814 drug Substances 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 5
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 5
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
229940068968 polysorbate 80 Drugs 0.000 description 5
229920000053 polysorbate 80 Polymers 0.000 description 5
238000003756 stirring Methods 0.000 description 5
229920000168 Microcrystalline cellulose Polymers 0.000 description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
239000000796 flavoring agent Substances 0.000 description 4
238000005187 foaming Methods 0.000 description 4
238000000034 method Methods 0.000 description 4
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
235000019813 microcrystalline cellulose Nutrition 0.000 description 4
235000019333 sodium laurylsulphate Nutrition 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
235000019640 taste Nutrition 0.000 description 4
235000019634 flavors Nutrition 0.000 description 3
235000003599 food sweetener Nutrition 0.000 description 3
239000000463 material Substances 0.000 description 3
229940068965 polysorbates Drugs 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000003765 sweetening agent Substances 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
238000013019 agitation Methods 0.000 description 2
235000019658 bitter taste Nutrition 0.000 description 2
239000000872 buffer Substances 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
-1 fatty acid esters Chemical class 0.000 description 2
239000006260 foam Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
239000002609 medium Substances 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
229960002216 methylparaben Drugs 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
239000000230 xanthan gum Substances 0.000 description 2
229920001285 xanthan gum Polymers 0.000 description 2
235000010493 xanthan gum Nutrition 0.000 description 2
229940082509 xanthan gum Drugs 0.000 description 2
LRZSAGKIMYFLHY-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;dihydrate Chemical compound O.O.OC(=O)CC(O)(C(O)=O)CC(O)=O LRZSAGKIMYFLHY-UHFFFAOYSA-N 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
244000144730 Amygdalus persica Species 0.000 description 1
244000099147 Ananas comosus Species 0.000 description 1
235000007119 Ananas comosus Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
244000037364 Cinnamomum aromaticum Species 0.000 description 1
235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
235000008733 Citrus aurantifolia Nutrition 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
235000019499 Citrus oil Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
240000000560 Citrus x paradisi Species 0.000 description 1
239000001692 EU approved anti-caking agent Substances 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
244000004281 Eucalyptus maculata Species 0.000 description 1
235000016623 Fragaria vesca Nutrition 0.000 description 1
240000009088 Fragaria x ananassa Species 0.000 description 1
235000011363 Fragaria x ananassa Nutrition 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
229920000161 Locust bean gum Polymers 0.000 description 1
241000220225 Malus Species 0.000 description 1
235000011430 Malus pumila Nutrition 0.000 description 1
235000015103 Malus silvestris Nutrition 0.000 description 1
240000005561 Musa balbisiana Species 0.000 description 1
235000018290 Musa x paradisiaca Nutrition 0.000 description 1
235000009421 Myristica fragrans Nutrition 0.000 description 1
244000270834 Myristica fragrans Species 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
235000009827 Prunus armeniaca Nutrition 0.000 description 1
244000018633 Prunus armeniaca Species 0.000 description 1
235000003893 Prunus dulcis var amara Nutrition 0.000 description 1
235000006040 Prunus persica var persica Nutrition 0.000 description 1
235000014443 Pyrus communis Nutrition 0.000 description 1
240000001987 Pyrus communis Species 0.000 description 1
240000007651 Rubus glaucus Species 0.000 description 1
235000011034 Rubus glaucus Nutrition 0.000 description 1
235000009122 Rubus idaeus Nutrition 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
240000006909 Tilia x europaea Species 0.000 description 1
235000011941 Tilia x europaea Nutrition 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
235000009499 Vanilla fragrans Nutrition 0.000 description 1
244000263375 Vanilla tahitensis Species 0.000 description 1
235000012036 Vanilla tahitensis Nutrition 0.000 description 1
235000009754 Vitis X bourquina Nutrition 0.000 description 1
235000012333 Vitis X labruscana Nutrition 0.000 description 1
240000006365 Vitis vinifera Species 0.000 description 1
235000014787 Vitis vinifera Nutrition 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229960004543 anhydrous citric acid Drugs 0.000 description 1
239000010617 anise oil Substances 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000010620 bay oil Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000012512 bulk drug substance Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229940119201 cedar leaf oil Drugs 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
239000007958 cherry flavor Substances 0.000 description 1
239000010630 cinnamon oil Substances 0.000 description 1
239000010500 citrus oil Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000000686 essence Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
239000000416 hydrocolloid Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
239000004571 lime Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000000711 locust bean gum Substances 0.000 description 1
235000010420 locust bean gum Nutrition 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000001525 mentha piperita l. herb oil Substances 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
239000001702 nutmeg Substances 0.000 description 1
229940100692 oral suspension Drugs 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
235000019477 peppermint oil Nutrition 0.000 description 1
230000035699 permeability Effects 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000007971 pharmaceutical suspension Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
235000002020 sage Nutrition 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
239000001789 thuja occidentalis l. leaf oil Substances 0.000 description 1
239000010678 thyme oil Substances 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Dental Preparations (AREA)
Chemical Or Physical Treatment Of Fibers (AREA)
Diaphragms For Electromechanical Transducers (AREA)
Colloid Chemistry (AREA)
General Preparation And Processing Of Foods (AREA)
Cosmetics (AREA)

OA1200100304A 1999-05-27 2000-05-08 Ziprasidone suspension. OA11946A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US13626899P	1999-05-27	1999-05-27

Publications (1)

Publication Number	Publication Date
OA11946A true OA11946A (en)	2006-04-13

Family

ID=22472103

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200100304A OA11946A (en)	1999-05-27	2000-05-08	Ziprasidone suspension.

Country Status (50)

Country	Link
EP (1)	EP1181018B1 (fr)
JP (1)	JP3942827B2 (fr)
KR (1)	KR100477782B1 (fr)
CN (1)	CN1196486C (fr)
AP (1)	AP1409A (fr)
AR (1)	AR022643A1 (fr)
AT (1)	ATE234097T1 (fr)
AU (1)	AU777413B2 (fr)
BG (1)	BG65367B1 (fr)
BR (1)	BR0010990A (fr)
CA (1)	CA2371550C (fr)
CO (1)	CO5170458A1 (fr)
CR (1)	CR6506A (fr)
CU (1)	CU23223B7 (fr)
CZ (1)	CZ20014230A3 (fr)
DE (1)	DE60001649T2 (fr)
DK (1)	DK1181018T3 (fr)
DZ (1)	DZ3049A1 (fr)
EA (1)	EA003907B1 (fr)
EE (1)	EE04704B1 (fr)
ES (1)	ES2191618T3 (fr)
GC (1)	GC0000190A (fr)
GE (1)	GEP20033113B (fr)
GT (1)	GT200000081A (fr)
HK (1)	HK1046366B (fr)
HN (1)	HN2000000071A (fr)
HR (1)	HRP20010878B1 (fr)
HU (1)	HUP0201297A3 (fr)
IL (2)	IL145950A0 (fr)
IS (1)	IS2396B (fr)
MA (1)	MA26741A1 (fr)
MX (1)	MXPA01012124A (fr)
MY (1)	MY127891A (fr)
NO (1)	NO320296B1 (fr)
NZ (1)	NZ514764A (fr)
OA (1)	OA11946A (fr)
PA (1)	PA8495801A1 (fr)
PE (1)	PE20010127A1 (fr)
PL (1)	PL196867B1 (fr)
RS (1)	RS50089B (fr)
SI (1)	SI1181018T1 (fr)
SK (1)	SK284590B6 (fr)
SV (1)	SV2001000085A (fr)
TN (1)	TNSN00112A1 (fr)
TR (1)	TR200103392T2 (fr)
TW (1)	TWI263498B (fr)
UA (1)	UA59491C2 (fr)
UY (1)	UY26166A1 (fr)
WO (1)	WO2000072847A1 (fr)
ZA (1)	ZA200109692B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7175855B1 (en)	1999-05-27	2007-02-13	Pfizer Inc.	Ziprasidone suspension
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
ATE526950T1 (de)	1999-10-29	2011-10-15	Euro Celtique Sa	Hydrocodon-formulierungen mit gesteuerter freisetzung
EP2283829A1 (fr)	2000-10-30	2011-02-16	Euro-Celtique S.A.	Formulations d'hydrocodone à liberation lente
WO2003077842A2 (fr) *	2002-03-12	2003-09-25	Bristol-Myers Squibb Company	Suspension orale de gout agreable et procede associe
JP2006505579A (ja) *	2002-10-25	2006-02-16	ファイザー・プロダクツ・インク	懸濁形態でのアリール複素環活性薬物の蓄積製剤
JP2006514923A (ja) *	2002-10-25	2006-05-18	ファイザー・プロダクツ・インク	注射可能な新規なデポ製剤
EP1418492B1 (fr)	2002-11-05	2017-09-20	LG Electronics, Inc.	Assemblage pour le montage d'un écran tactile pour un affichage à cristaux liquides
CA2543805A1 (fr)	2003-10-24	2005-05-06	Gideon Pilarsky	Procedes de preparation de ziprasidone
WO2005107719A2 (fr)	2004-05-06	2005-11-17	Sandoz Ag	Composition pharmaceutique comprenant un medicament hydrophobe a solubilite amelioree
US20070237828A1 (en) *	2004-06-11	2007-10-11	Dr. Reddy's Laboratories Limited	Ziprasidone Dosage Form
WO2006085168A2 (fr) *	2005-01-07	2006-08-17	Ranbaxy Laboratories Limited	Formes de dosage orales solides de ziprasidone
EP1901722A4 (fr) *	2005-06-20	2011-06-15	Elan Pharma Int Ltd	Compositions de nanoparticules à libération contrôlée comprenant des composés d'aryle hétérocyclique
WO2007052289A2 (fr)	2005-07-22	2007-05-10	Rubicon Research Pvt Ltd.	Nouvelle composition de comprime dispersible
CN100391458C (zh) *	2006-02-07	2008-06-04	上海医药工业研究院	齐拉西酮或其盐包合物制备方法
KR20080076667A (ko) *	2007-02-15	2008-08-20	주식회사 중외제약	요변성 약학 조성물
JP4336380B1 (ja) *	2008-11-06	2009-09-30	塩野義製薬株式会社	水懸濁性を向上させた細粒剤
JP6272730B2 (ja) *	2014-05-21	2018-01-31	救急薬品工業株式会社	速溶性フィルム剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4831031A (en) *	1988-01-22	1989-05-16	Pfizer Inc.	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) *	1992-09-01	1994-05-17	Pfizer Inc.	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US6150366A (en) *	1998-06-15	2000-11-21	Pfizer Inc.	Ziprasidone formulations

2000
- 2000-05-08 PL PL352826A patent/PL196867B1/pl not_active IP Right Cessation
- 2000-05-08 CA CA002371550A patent/CA2371550C/fr not_active Expired - Lifetime
- 2000-05-08 SI SI200030060T patent/SI1181018T1/xx unknown
- 2000-05-08 IL IL14595000A patent/IL145950A0/xx active IP Right Grant
- 2000-05-08 CN CNB008081204A patent/CN1196486C/zh not_active Expired - Fee Related
- 2000-05-08 EP EP00920981A patent/EP1181018B1/fr not_active Expired - Lifetime
- 2000-05-08 AT AT00920981T patent/ATE234097T1/de not_active IP Right Cessation
- 2000-05-08 KR KR10-2001-7015090A patent/KR100477782B1/ko not_active Expired - Fee Related
- 2000-05-08 HK HK02107882.4A patent/HK1046366B/zh not_active IP Right Cessation
- 2000-05-08 ES ES00920981T patent/ES2191618T3/es not_active Expired - Lifetime
- 2000-05-08 BR BR0010990-8A patent/BR0010990A/pt not_active Application Discontinuation
- 2000-05-08 HR HR20010878A patent/HRP20010878B1/xx not_active IP Right Cessation
- 2000-05-08 TR TR2001/03392T patent/TR200103392T2/xx unknown
- 2000-05-08 EE EEP200100633A patent/EE04704B1/xx not_active IP Right Cessation
- 2000-05-08 DK DK00920981T patent/DK1181018T3/da active
- 2000-05-08 NZ NZ514764A patent/NZ514764A/en unknown
- 2000-05-08 HU HU0201297A patent/HUP0201297A3/hu unknown
- 2000-05-08 AP APAP/P/2001/002346A patent/AP1409A/en active
- 2000-05-08 AU AU41385/00A patent/AU777413B2/en not_active Ceased
- 2000-05-08 MX MXPA01012124A patent/MXPA01012124A/es active IP Right Grant
- 2000-05-08 GE GEAP20006213A patent/GEP20033113B/en unknown
- 2000-05-08 CZ CZ20014230A patent/CZ20014230A3/cs unknown
- 2000-05-08 DE DE60001649T patent/DE60001649T2/de not_active Expired - Lifetime
- 2000-05-08 SK SK1678-2001A patent/SK284590B6/sk not_active IP Right Cessation
- 2000-05-08 JP JP2000620959A patent/JP3942827B2/ja not_active Expired - Lifetime
- 2000-05-08 EA EA200101131A patent/EA003907B1/ru not_active IP Right Cessation
- 2000-05-08 WO PCT/IB2000/000593 patent/WO2000072847A1/fr not_active Ceased
- 2000-05-08 OA OA1200100304A patent/OA11946A/en unknown
- 2000-05-08 RS YUP-767/01A patent/RS50089B/sr unknown
- 2000-05-10 HN HN2000000071A patent/HN2000000071A/es unknown
- 2000-05-19 PA PA20008495801A patent/PA8495801A1/es unknown
- 2000-05-22 PE PE2000000480A patent/PE20010127A1/es not_active Application Discontinuation
- 2000-05-23 GC GCP2000670 patent/GC0000190A/en active
- 2000-05-23 TW TW089109949A patent/TWI263498B/zh active
- 2000-05-24 DZ DZ000093A patent/DZ3049A1/fr active
- 2000-05-24 MA MA25991A patent/MA26741A1/fr unknown
- 2000-05-24 MY MYPI20002273A patent/MY127891A/en unknown
- 2000-05-24 TN TNTNSN00112A patent/TNSN00112A1/fr unknown
- 2000-05-24 CO CO00038317A patent/CO5170458A1/es not_active Application Discontinuation
- 2000-05-25 UY UY26166A patent/UY26166A1/es not_active Application Discontinuation
- 2000-05-25 GT GT200000081A patent/GT200000081A/es unknown
- 2000-05-26 SV SV2000000085A patent/SV2001000085A/es not_active Application Discontinuation
- 2000-05-26 AR ARP000102585A patent/AR022643A1/es active IP Right Grant
- 2000-08-05 UA UA2001118094A patent/UA59491C2/uk unknown
2001
- 2001-10-15 IL IL145950A patent/IL145950A/en unknown
- 2001-10-30 IS IS6134A patent/IS2396B/is unknown
- 2001-11-19 CU CU20010266A patent/CU23223B7/es not_active IP Right Cessation
- 2001-11-23 CR CR6506A patent/CR6506A/es not_active Application Discontinuation
- 2001-11-26 NO NO20015755A patent/NO320296B1/no unknown
- 2001-11-26 ZA ZA200109692A patent/ZA200109692B/en unknown
- 2001-11-26 BG BG106153A patent/BG65367B1/bg unknown

Also Published As

Publication number	Publication date
AP1409A (en)	2005-06-13
SV2001000085A (es)	2001-11-08
NO20015755L (no)	2002-01-23
JP3942827B2 (ja)	2007-07-11
IS2396B (is)	2008-08-15
DZ3049A1 (fr)	2004-03-27
SI1181018T1 (en)	2003-06-30
EA003907B1 (ru)	2003-10-30
TWI263498B (en)	2006-10-11
CA2371550A1 (fr)	2000-12-07
EE200100633A (et)	2003-02-17
HK1046366B (zh)	2005-07-29
MA26741A1 (fr)	2004-12-20
MXPA01012124A (es)	2002-06-04
JP2003500449A (ja)	2003-01-07
DE60001649T2 (de)	2003-08-21
KR20020048307A (ko)	2002-06-22
NZ514764A (en)	2004-04-30
CN1196486C (zh)	2005-04-13
BG106153A (bg)	2002-06-28
CO5170458A1 (es)	2002-06-27
AR022643A1 (es)	2002-09-04
HUP0201297A2 (en)	2002-08-28
IS6134A (is)	2001-10-30
EE04704B1 (et)	2006-10-16
GT200000081A (es)	2001-11-16
SK284590B6 (sk)	2005-07-01
CU23223B7 (es)	2007-08-30
CA2371550C (fr)	2007-01-02
EP1181018A1 (fr)	2002-02-27
BG65367B1 (bg)	2008-04-30
AU777413B2 (en)	2004-10-14
NO320296B1 (no)	2005-11-21
PL352826A1 (en)	2003-09-08
EA200101131A1 (ru)	2002-04-25
MY127891A (en)	2006-12-29
UA59491C2 (uk)	2003-09-15
CR6506A (es)	2004-03-24
DK1181018T3 (da)	2003-04-22
SK16782001A3 (sk)	2002-09-10
BR0010990A (pt)	2002-03-05
HN2000000071A (es)	2001-02-02
HRP20010878B1 (en)	2007-03-31
DE60001649D1 (de)	2003-04-17
KR100477782B1 (ko)	2005-03-21
GC0000190A (en)	2006-03-29
UY26166A1 (es)	2000-12-29
PE20010127A1 (es)	2001-02-06
TR200103392T2 (tr)	2002-11-21
PL196867B1 (pl)	2008-02-29
HK1046366A1 (en)	2003-01-10
AU4138500A (en)	2000-12-18
AP2001002346A0 (en)	2001-12-31
ZA200109692B (en)	2002-11-26
CN1352560A (zh)	2002-06-05
WO2000072847A1 (fr)	2000-12-07
RS50089B (sr)	2009-01-22
PA8495801A1 (es)	2001-12-14
ATE234097T1 (de)	2003-03-15
NO20015755D0 (no)	2001-11-26
IL145950A0 (en)	2002-07-25
GEP20033113B (en)	2003-11-25
IL145950A (en)	2007-12-03
HRP20010878A2 (en)	2003-06-30
ES2191618T3 (es)	2003-09-16
EP1181018B1 (fr)	2003-03-12
TNSN00112A1 (fr)	2005-11-10
CZ20014230A3 (cs)	2002-08-14
YU76701A (sh)	2005-07-19
HUP0201297A3 (en)	2005-09-28

Publication	Publication Date	Title
CA2371550C (fr)	2007-01-02	Suspension de ziprasidone
JP2847134B2 (ja)	1999-01-13	経口投与用イブプロフェン組成物
US8772317B2 (en)	2014-07-08	Aqueous pharmaceutical suspensions containing rebamipide and manufacturing process thereof
KR960012397B1 (ko)	1996-09-20	시메티딘을 함유하는 조성물
JP3631782B2 (ja)	2005-03-23	ウルソデオキシコール酸を含む液体投与形態の薬剤
JP2002509875A (ja)	2002-04-02	経口活性剤懸濁液
IE65240B1 (en)	1995-10-04	Pediatric ibuprofen formulations
JP2000344770A (ja)	2000-12-12	トロバフロキサシン経口懸濁剤
WO1990011077A1 (fr)	1990-10-04	Composition de spironolactone
US20070134323A1 (en)	2007-06-14	Ziprasidone suspension
JP2003505421A (ja)	2003-02-12	ピバリン酸チクソコルトール懸濁液、それをベースとするうがい剤、及びそれを含有するパッケージ
KR20080018006A (ko)	2008-02-27	메게스트롤 아세테이트의 서상화된 현탁제